Operator of an immunology company intended to harness the power of the immune system to develop treatments for cancer an
Operator of an immunology company intended to harness the power of the immune system to develop treatments for cancer and autoimmune diseases.
Drug Discovery📍 South San Francisco, CAFounded 2014
Current Valuation
$601.2M
as of 2020-Q3
PRIVATE
QL Price
$601.2M
0% vs last round
QuantLogix's current estimate for Tizona Therapeutics, published 2026-09-27 — in line with the last disclosed round of $601.2M (2020-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$601.2M
2020-Q3
weight 0.02
How this price has held up
No round has priced for Tizona Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Tizona Therapeutics, 2026-09-27 (13ea916b7cd0e9e0).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Tizona Therapeutics going public?
No. Tizona Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Tizona Therapeutics' valuation in 2026?
Tizona Therapeutics is valued at $601.2M as of 2020-Q3, set by its Later Stage VC ($300M, Jul 2020). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Tizona Therapeutics filed an S-1?
No public S-1 is on file for Tizona Therapeutics.
How much has Tizona Therapeutics raised?
Tizona Therapeutics has raised $520M in total, most recently a Later Stage VC of $300M in Jul 2020.
Is Tizona Therapeutics publicly traded — can you buy Tizona Therapeutics stock?
No. Tizona Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Tizona Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2014
HQ
South San Francisco, CA
Employees
24
Total Raised
$520M
Last Round
Later Stage VC — $300M (Jul 2020)
IPO Status
private
Fundraising Status
Later Stage VC · $300M · 6y 2mo ago
privateTotal raised $520M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$300M
Jul 2020
—
$601.2M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
1 active · 0 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
Cancer
Latest trial start
2020-07-14
Name-verified against lead sponsor "Tizona Therapeutics, Inc" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Tizona Therapeutics as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
MedicalBiotechnologyTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2020-Q3. Refreshed quarterly.